Abstract
The clinical effect of gatifloxacin (GFLX) at 200 mg daily (half of common dosage) on bacterial community-acquired pneumonia in the elderly was examined. Subjects were 30 patients with bacterial community-acquired pneumonia aged 65 years or more (mild, 21 patients; moderate, 9 patients), and GFLX at 100 mg per dose was administered twice daily for 4–14 days. The results included clinical effectiveness in 21 of 21 mildly affected patients (efficacy rate, 100%), in 8 of 9 moderately affected patients (efficacy rate, 88.9%), and 29 of a total of 30 patients (efficacy rate, 96.7%). With regard to bacteriological effect, 28 of 29 strains were eradicated (eradication rate, 96.6%). Abnormal laboratory findings included mild elevations in GPT, GOT, and ALP in only 1 patient. Based on these findings, we concluded that administration of GFLX at 200 mg daily is recommended for bacterial community-acquired pneumonia in the elderly.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
H Fukuda Y Oomori T Yamamoto T Yasue H Tomizawa S Hori et al. (1999) ArticleTitleThe in vitro antibacterial activity of gatifloxacin, a new quinolone antimicrobial agent (in Japanese) Jpn J Chemother 47 IssueIDS-2 3–11 Occurrence Handle1:CAS:528:DyaK1MXmsFCru78%3D
N Miyashita Y Niki T Kishimoto M Nakajima T Matsushima (1997) ArticleTitleIn vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp Antimicrob Agents Chemother 41 1331–4 Occurrence Handle9174194 Occurrence Handle1:CAS:528:DyaK2sXjsFCntbs%3D
A Saito T Koike K Taneichi T Takeda K Takeuchi M Ohmichi et al. (1999) ArticleTitleA double-blind comparative study of gatifloxacin and levofloxacin in pneumonia (in Japanese) Jpn J Chemother 47 712–33
FP LaCreta GD Kollia G Duncan D Behr D Grasela (2000) ArticleTitleAge and gender effects on the pharmacokinetics of gatifloxacin Pharmacotherapy 20 67–75
InstitutionalAuthorNameThe Committee of the Japanese Respiratory Society (2000) Guidelines of management for community-acquired pneumonia: the basic concept of management for community-acquired pneumonia in adults (in Japanese) Kyorinsya Tokyo 1–13
InstitutionalAuthorNameThe report of the Committee for the Respiratory System, the Committee of Clinical Evaluation Methods for Antibiotics, Japanese Society of Chemotherapy (1997) ArticleTitleClinical evaluation method for new antimicrobial agents to treat respiratory infections (draft) (in Japanese) Jpn J Chemother 45 762–78
T Ishida T Hashimoto M Arita Y Tojo H Tachibana M Jinnai (2004) ArticleTitleA 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology J Infect Chemother 10 359–63 Occurrence Handle15614462 Occurrence Handle1:CAS:528:DC%2BD2cXhtFWqsbbI Occurrence Handle10.1007/s10156-004-0351-1
PG Ambrose SM Bhavnani BB Cirincione M Piedmonte TH Grasela (2003) ArticleTitleGatifloxacin and the elderly: pharmacokinetic-pharmocodynamic rationale for a potential age-related dose reduction J Antimicrob Chemother 52 435–40 Occurrence Handle12917247 Occurrence Handle1:CAS:528:DC%2BD3sXnt1Kjtbs%3D Occurrence Handle10.1093/jac/dkg370
HM Mattoes M Banevicius D Li C Turley D Xuan CH Nightingale et al. (2001) ArticleTitlePharmocodynamic assessment of gatifloxacin against Streptococcus pneumoniae Antimicrob Agents Chemother 45 2092–7 Occurrence Handle11408228 Occurrence Handle1:CAS:528:DC%2BD3MXks1Gks7c%3D Occurrence Handle10.1128/AAC.45.7.2092-2097.2001
PD Lister (2002) ArticleTitlePharmocodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication Antimicrob Agents Chemother 46 69–74 Occurrence Handle11751113 Occurrence Handle1:CAS:528:DC%2BD38XjtVaqsQ%3D%3D Occurrence Handle10.1128/AAC.46.1.69-74.2002
N Aoki K Shiba (1999) ArticleTitlePharmacokinetics of gatifloxacin, a new quinolone, in elderly patients (in Japanese) Jpn J Chemother 47 IssueIDS-2 230–7 Occurrence Handle1:CAS:528:DyaK1MXmsFCqs7o%3D
RN Jones CM Rubino SM Bhavnani PG Ambrose (2003) ArticleTitleWorldwide antimicrobial susceptibility patterns and pharmocodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the antimicrobial resistance rate epidemiology study team Antimicrob Agents Chemother 47 292–6 Occurrence Handle12499204 Occurrence Handle1:CAS:528:DC%2BD3sXis12msw%3D%3D
J Smayevsky H Lopez MD Chiara S Scarano A Lanza V Vilches et al. (2000) ArticleTitleActivity of gatifoxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection Diagn Microbiol Infect Dis 37 261–4 Occurrence Handle10974577 Occurrence Handle1:CAS:528:DC%2BD3cXmtF2qs70%3D Occurrence Handle10.1016/S0732-8893(00)00159-0
K Yamaguchi N Furuya M Iwata N Watanabe N Uehara M Yasujima et al. (2004) ArticleTitleSurveillance of susceptibility of 2,228 clinical isolates to gatifloxacin and various antimicrobial agents (in Japanese) Jpn J Chemother 52 771–86
AR Donaldson JR Vandium CK Finch (2004) ArticleTitlePossible gatifloxacin-induced hyperglycemia Ann Pharmacother 38 602–5 Occurrence Handle14982977
N Maeda T Tamagawa I Niki H Miura K Ozawa G Watanabe et al. (1996) ArticleTitleIncrease in insulin release from rat pancreatic islets by quinolone antibiotics Br J Pharmacol 117 372–6 Occurrence Handle8789393 Occurrence Handle1:CAS:528:DyaK28XnslKitw%3D%3D
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Okimoto, N., Kibayashi, T., Mimura, K. et al. Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly. J Infect Chemother 11, 274–277 (2005). https://doi.org/10.1007/s10156-005-0410-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10156-005-0410-2